Advertisement
Screener

Celldex Therapeutics, Inc. (CLDX) Proceeds from Long-Term Debt Issued

2.8 / 5 stars · 68/120 Roast Me

Celldex Therapeutics, Inc. Proceeds from Long-Term Debt Issued

Celldex Therapeutics, Inc. (CLDX) reported Proceeds from Long-Term Debt Issued of -$11.03 million for the 12-month period ending 2013-12-31, per its 10-K filed 2014-03-03.

Discontinued › Cash Flow › Financing Activities

us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2014-03-03

  • Celldex Therapeutics, Inc. proceeds from issuance of long-term debt for the quarter ending 2013-06-30 was -$9.71M.
  • Celldex Therapeutics, Inc. proceeds from issuance of long-term debt for the quarter ending 2013-03-31 was -$1.32M.
  • Celldex Therapeutics, Inc. proceeds from issuance of long-term debt for the quarter ending 2012-12-31 was -$1.32M.
  • Celldex Therapeutics, Inc. proceeds from issuance of long-term debt for the quarter ending 2012-09-30 was -$1.32M.
  • Celldex Therapeutics, Inc. proceeds from issuance of long-term debt for fiscal 2013 was -$11.03M.
  • Celldex Therapeutics, Inc. proceeds from issuance of long-term debt for fiscal 2012 was -$3.97M, a 179.42% decline from fiscal 2011.
  • Celldex Therapeutics, Inc. proceeds from issuance of long-term debt for fiscal 2011 was $5.00M, a 50.00% decline from fiscal 2010.
  • Celldex Therapeutics, Inc. proceeds from issuance of long-term debt for fiscal 2010 was $10.00M.
Period endProceeds from Issuance of Long-term Debt 3 monthProceeds from Issuance of Long-term Debt 6 monthProceeds from Issuance of Long-term Debt 9 monthProceeds from Issuance of Long-term Debt 12 month
2013-12-31-$11.03M
10-K · filed 2014-03-03
2013-06-30-$9.71M
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06
-$11.03M
10-Q · filed 2013-08-06
-$12.35M
derived: sum of 3 quarters · filed 2014-03-03
-$13.68M
derived: sum of 4 quarters · filed 2014-03-03
2013-03-31-$1.32M
10-Q · filed 2013-05-03
-$2.65M
derived: sum of 2 quarters · filed 2014-03-03
-$3.97M
derived: sum of 3 quarters · filed 2014-03-03
2012-12-31-$1.32M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03
-$2.65M
derived: sum of 2 quarters · filed 2014-03-03
-$3.97M
10-K · filed 2014-03-03
2012-09-30-$1.32M
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-02
-$2.65M
10-Q · filed 2012-11-02
2012-06-30-$1.32M
10-Q · filed 2013-08-06
2011-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03
$0.00
derived: sum of 2 quarters · filed 2014-03-03
$0.00
derived: sum of 3 quarters · filed 2014-03-03
$5.00M
10-K · filed 2014-03-03
2011-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-02
$0.00
derived: sum of 2 quarters · filed 2012-11-02
$5.00M
10-Q · filed 2012-11-02
2011-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09
$5.00M
10-Q · filed 2012-08-09
2011-03-31$5.00M
10-Q · filed 2012-05-04
2010-12-31$10.00M
10-K · filed 2013-03-08

Similar stocks

Stock NameCountryMarket CapPE Ratio
NEOGEN CORP (NEOG)United States$2.979B-247.49
Intellia Therapeutics, Inc. (NTLA)United States$1.705B-5.92
ACHIEVE LIFE SCIENCES, INC. (ACHV)United States$0.806B-5.88
QuidelOrtho Corp (QDEL)United States$0.733B-0.90
Alpha Teknova, Inc. (TKNO)United States$0.500B-18.12
MYRIAD GENETICS INC (MYGN)United States$0.397B-4.84
Insight Molecular Diagnostics Inc. (IMDX)United States$0.129B-3.90
IMMUCELL CORP /DE/ (ICCC)United States$0.091B116.10
BIOMERICA INC (BMRA)United States$0.011B
Q/C TECHNOLOGIES, INC. (QCLS)United States$0.008B-1.93